Dihydroartemisinin, an Anti-Malaria Drug, Suppresses Estrogen Deficiency-Induced Osteoporosis, Osteoclast Formation, and RANKL-Induced Signaling Pathways
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dihydroartemisinin, an Anti-Malaria Drug, Suppresses Estrogen Deficiency-Induced Osteoporosis, Osteoclast Formation, and RANKL-Induced Signaling Pathways
Authors
Keywords
-
Journal
JOURNAL OF BONE AND MINERAL RESEARCH
Volume 31, Issue 5, Pages 964-974
Publisher
Wiley
Online
2015-12-19
DOI
10.1002/jbmr.2771
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeted Efficacy of Dihydroartemisinin for Translationally Controlled Protein Expression in a Lung Cancer Model
- (2014) Lian-Ke Liu et al. Asian Pacific Journal of Cancer Prevention
- Dihydroartemisinin targets VEGFR2 via the NF-κB pathway in endothelial cells to inhibit angiogenesis
- (2014) Fengyun Dong et al. CANCER BIOLOGY & THERAPY
- Population pharmacokinetics of artesunate and dihydroartemisinin during long-term oral administration of artesunate to patients with metastatic breast cancer
- (2014) Therese Ericsson et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- SC-514, a selective inhibitor of IKKβ attenuates RANKL-induced osteoclastogenesis and NF-κB activation
- (2013) Qian Liu et al. BIOCHEMICAL PHARMACOLOGY
- An overview of the regulation of bone remodelling at the cellular level
- (2012) Jasreen Kular et al. CLINICAL BIOCHEMISTRY
- Growth inhibitory effect of dihydroartemisinin on Bcr/Abl+ chronic myeloid leukemia K562 cells involve AKT, ERK and NF-κB modulation
- (2012) Jun Lee et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- NIH Image to ImageJ: 25 years of image analysis
- (2012) Caroline A Schneider et al. NATURE METHODS
- EGFL6 Promotes Endothelial Cell Migration and Angiogenesis through the Activation of Extracellular Signal-regulated Kinase
- (2011) Shek Man Chim et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Anti-tumor effects of dihydroartemisinin on human osteosarcoma
- (2011) Ye Ji et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Integrins, growth factors, and the osteoclast cytoskeleton
- (2010) Wei Zou et al. Annals of the New York Academy of Sciences
- Suppression of PMA-induced tumor cell invasion by dihydroartemisinin via inhibition of PKCα/Raf/MAPKs and NF-κB/AP-1-dependent mechanisms
- (2010) Yong Pil Hwang et al. BIOCHEMICAL PHARMACOLOGY
- Osteoporosis: impact on health and economics
- (2010) Nicholas Harvey et al. Nature Reviews Rheumatology
- Myocyte Enhancer Factor 2 and Microphthalmia-associated Transcription Factor Cooperate with NFATc1 to Transactivate the V-ATPase d2 Promoter during RANKL-induced Osteoclastogenesis
- (2009) HaoTian Feng et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Growth inhibitory effects of dihydroartemisinin on pancreatic cancer cells: involvement of cell cycle arrest and inactivation of nuclear factor-κB
- (2009) Hua Chen et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Osteoimmunology and the effects of the immune system on bone
- (2009) Hiroshi Takayanagi Nature Reviews Rheumatology
- NF-κB modulators in osteolytic bone diseases
- (2008) Jiake Xu et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Artemisinins: their growing importance in medicine
- (2008) Sanjeev Krishna et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- The roles of the classical and alternative nuclear factor-kappaB pathways: potential implications for autoimmunity and rheumatoid arthritis
- (2008) Keith D Brown et al. ARTHRITIS RESEARCH & THERAPY
- NFATc1 Induces Osteoclast Fusion Via Up-Regulation of Atp6v0d2 and the Dendritic Cell-Specific Transmembrane Protein (DC-STAMP)
- (2007) Kabsun Kim et al. MOLECULAR ENDOCRINOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started